Twist Bioscience Corp
Congressional Trades
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
Dwight EvansHouse · D · PA |
TWSTTwist Bioscience Corp · Stock |
Sale $1,001 - $15,000 |
Apr 25, 2022 | Mar 30, 2022 | Filing ↗ |
Dwight EvansHouse · D · PA |
TWSTTwist Bioscience Corp · Stock |
Purchase $1,001 - $15,000 |
Apr 23, 2020 | Mar 2, 2020 | Filing ↗ |
Whale Activity
- Increased127
- New132
- Held37
- Decreased120
- Closed39
- No prior filing21
| Filer | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 9.7M | $1.87B | increased |
| BlackRock, Inc. | 6.4M | $1.23B | increased |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6.1M | $1.18B | increased |
| ARK Investment Management LLC | 3.4M | $656.6M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.1M | $603.4M | increased |
| STATE STREET CORP | 3.0M | $583.0M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $575.3M | increased |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.1M | $412.8M | held |
| Artisan Partners Limited Partnership | 2.0M | $395.1M | decreased |
| D. E. Shaw & Co., Inc. | 1.8M | $352.9M | increased |
| Invesco Ltd. | 1.8M | $352.1M | decreased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7M | $336.2M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Cho DennisSee Remarks | Sale | −5,427 | $103.69 | $563K | Nov 16, 2026 | Form 4 ↗ |
| Finn Patrick JohnPresident and COO | Sale | −12.8K | $103.69 | $1.3M | Nov 16, 2026 | Form 4 ↗ |
| Green PaulaSVP of Human Resources | Sale | −4,281 | $103.69 | $444K | Nov 16, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −19.0K | $103.69 | $2.0M | Nov 16, 2026 | Form 4 ↗ |
| WERNER ROBERT F.Chief Accounting Officer | Sale | −1,637 | $103.69 | $170K | Nov 16, 2026 | Form 4 ↗ |
| Laponis AdamChief Financial Officer | Sale | −6,359 | $103.69 | $659K | Nov 16, 2026 | Form 4 ↗ |
| Green PaulaSVP of Human Resources | Sale | +20.4K | $0.00 | $0 | Nov 12, 2026 | Form 4 ↗ |
| Cho DennisSee Remarks | Sale | −949 | $135.40 | $128K | Nov 3, 2026 | Form 4 ↗ |
| Finn Patrick JohnPresident and COO | Sale | −2,565 | $135.40 | $347K | Nov 3, 2026 | Form 4 ↗ |
| Green PaulaSVP of Human Resources | Sale | −1,007 | $135.40 | $136K | Nov 3, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −4,573 | $135.40 | $619K | Nov 3, 2026 | Form 4 ↗ |
| WERNER ROBERT F.Chief Accounting Officer | Sale | −148 | $135.40 | $20K | Nov 3, 2026 | Form 4 ↗ |
| Finn Patrick JohnPresident and COO | Sale | −2,245 | $134.59 | $302K | Oct 23, 2026 | Form 4 ↗ |
| Laponis AdamChief Financial Officer | Sale | −2,462 | $156.30 | $385K | Oct 9, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −481 | $201.26 | $97K | Oct 5, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −45 | $207.46 | $9K | Oct 5, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −432 | $203.61 | $88K | Oct 5, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −297 | $205.78 | $61K | Oct 5, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −290 | $204.80 | $59K | Oct 5, 2026 | Form 4 ↗ |
| Leproust Emily M.Chief Executive Officer · Director | Sale | −1,840 | $200.44 | $369K | Oct 5, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.9M | $192.8M | 0.01% | Jun 30, 2026 |
| ARK Innovation ETF ARK ETF Trust | 2.0M | $184.1M | 3.31% | Jul 31, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.6M | $164.0M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.5M | $151.1M | 1.41% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 1.4M | $139.6M | 0.07% | Jun 30, 2026 |
| ARK Genomic Revolution ETF ARK ETF Trust | 1.3M | $120.4M | 7.73% | Jul 31, 2026 |
| Invesco Discovery Fund AIM Counselor Series Trust (Invesco Counselor Series Trust) | 835.6K | $116.1M | 1.57% | Aug 31, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 959.3K | $98.7M | 0.67% | Jun 30, 2026 |
| Artisan Mid Cap Fund Artisan Partners Funds Inc. | 893.2K | $91.9M | 2.88% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust | 866.9K | $89.2M | 0.80% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list TWST's shares (CUSIP 90184D100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 6.1M shares9.2%
Nov 16, 2026 · ↗ - Artisan Partners Limited PartnershipSCHEDULE 13G/A · passive (13G) · 2.0M shares3.4%
Nov 12, 2026 · ↗ - Artisan Investments GP LLCSCHEDULE 13G/A · passive (13G) · 2.0M shares3.4%
Nov 12, 2026 · ↗ - Artisan Partners Holdings LPSCHEDULE 13G/A · passive (13G) · 2.0M shares3.4%
Nov 12, 2026 · ↗ - Artisan Partners Asset Management Inc.SCHEDULE 13G/A · passive (13G) · 2.0M shares3.4%
Nov 12, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 3.0M shares4.6%
Nov 10, 2026 · ↗ - Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 9.5M shares14.4%
Nov 5, 2026 · ↗ - FMR LLCSCHEDULE 13G/A · passive (13G) · 9.5M shares14.4%
Nov 5, 2026 · ↗ - Catherine D. WoodSCHEDULE 13G/A · passive (13G) · 3.4M shares5.1%
Sep 8, 2026 · ↗ - ARK Investment Management LLCSCHEDULE 13G/A · passive (13G) · 3.4M shares5.1%
Sep 8, 2026 · ↗
Corporate Lobbying
- IPOLICY SOLUTIONSTWIST BIOSCIENCE CORPORATION · 2026 Q3 · SCI, TRD$83K
Filing ↗ - IPOLICY SOLUTIONSTWIST BIOSCIENCE CORPORATION · 2026 Q2 · SCI, TRD$83K
Filing ↗ - IPOLICY SOLUTIONSTWIST BIOSCIENCE CORPORATION · 2026 Q1 · SCI, TRD$83K
Filing ↗ - IPOLICY SOLUTIONSTWIST BIOSCIENCE CORPORATION · 2025 Q4 · SCI, DEF, TRD$75K
Filing ↗ - IPOLICY SOLUTIONSTWIST BIOSCIENCE CORPORATION · 2025 Q3 · INT, CPT, SCI$75K
Filing ↗
Government Contracts
- Department of Veterans AffairsSHAHRARA HUMANIZED MONOCLONAL ANTIBODY FOR SYNDECAN TWIST BIOSCIENCE$105K
Sep 18, 2024 · ↗ - Department of Health and Human ServicesTHE PURPOSE OF THIS PURCHASE ORDER IS TO PROVIDE THE NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES / DIVISION OF TRANSLATIONAL TOXICOL$27K
Jul 30, 2026 · ↗ - Department of Health and Human ServicesTWIST BIOSCIENCE$0
Dec 18, 2020 · ↗ - Department of JusticeTWIST BIOSCIENCE EQUIPMENT$97K
Jun 29, 2026 · ↗
U.S. Patents
No USPTO patent applications found for Twist Bioscience Corp.
Annual Financials
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Operating income | -$139.5M | -$136.3M | -$220.8M | -$217.2M | -$234.8M |
| Net income | -$130.2M | -$77.7M | -$208.7M | -$204.6M | -$217.9M |
| Diluted EPS | -$2.08 | -$1.30 | -$3.60 | -$3.60 | -$4.04 |
| Operating cash flow | -$41.4M | -$47.6M | -$64.1M | -$142.5M | -$124.4M |
| Cash and equivalents | $534.0M | $183.0M | $226.3M | $286.5M | $378.7M |
| Total assets | $1.12B | $641.9M | $614.3M | $776.4M | $961.4M |
| Total liabilities | $233.8M | $168.9M | $141.6M | $153.0M | $172.0M |
| Shareholders' equity | $888.0M | $473.0M | $472.7M | $623.4M | $789.4M |
As Twist Bioscience Corp tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Nov 16, 2026 ↗
Stock Splits
No stock splits in TWST's price history.
Material Events (8-K)
- 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
EDGAR ↗ - 8-K · Items 7.01Reg FD disclosureAug 19, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsAug 19, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureAug 5, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 3, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 4, 2026
EDGAR ↗
About Twist Bioscience Corp
Twist Bioscience Corporation provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. Across diagnostics, therapeutics, industrial, agriculture and research markets, our customers use our products and services to develop ways to improve human health and the sustainability of the planet. Our goal is to enable them to do this work with confidence, without having to compromise on quality, speed, scale or cost. We believe that the faster our customers succeed, the better for all of us. At the core of our business is a proprietary platform that allows us to manufacture synthetic DNA by “writing” DNA on a silicon chip. We have miniatur…

